# Matū Group

> Matū Group is a VC fund in Auckland backing Biotechnology, Health Care and Manufacturing. See 21 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Auckland, New Zealand
- Total investments: 21
- Last investment: Jun 2023
- Lead investor: 24%
- Last updated: Aug 2026
- Website: https://www.matu.co.nz

Matū Group is a VC fund in Auckland focused on Biotechnology and Health Care. Science and Technology

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $473k–$2.2M |
| Pre-Seed | $337k–$972k |
| Series A | $2.3M–$25M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 29% |
| Health Care | 5 | 24% |
| Manufacturing | 3 | 14% |
| Medical Device | 3 | 14% |
| Medical | 2 | 10% |

28 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 9 | 43% |
| Pre-Seed | 4 | 19% |
| Series A | 3 | 14% |
| Venture - Series Unknown | 1 | 5% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| New Zealand | 13 | 62% |
| Australia | 1 | 5% |
| United States | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Inhibit Coatings | Inhibit Coatings is a start-up company that produces high-performance antimicrobial paints and coatings for food safety and healthcare. It uses a unique silver nanoparticle functionalization method that produces physically robust, low-leaching, and long lifetime antimicrobial coatings.Its technology produces silver particles evenly dispersedthroughout the polymer coating and bound to the resin backbone. Only very small amounts of silver are required, typically less than 0.1%, owing to silver’s excellent and well-documented performance as an antimicrobial agent, with proven activity against over 650 different microorganisms. Its technology has been applied to a number of resin systems including acrylics, epoxies, and polyurethanes.It was founded by Dr. Eldon Tate and Prof. Jim Johnston in 2016. | $920.7K | Venture - Series Unknown | Jun 30, 2023 |  |
| Captivate Technology | Captivate Technology company operates a clean-tech carbon capture platform. The platform enables cement manufacturers, geothermal power plants, and biogas producers to reduce pollution and contribute to environmental initiatives by using a metal-organic framework for CO2 adsorption as a solid-state material. | $473.1K | Seed | Feb 10, 2023 |  |
| Advemto | Advemto is the manufacturer and developer of ultrafast spectroscopy systems that help researchers. | $681.9K | Pre-Seed | Jun 03, 2022 |  |
| Opo Bio | Opo Bio develops cell lines for the cultivated meat industry and researchers.They are building a multi-species and multi-cell type product bank for research and commercial usage. They are creating infrastructure that will enable the industry to progress and more effectively scale. | $971.8K | Pre-Seed | Jun 01, 2022 |  |
| Liquium | Liquium develops technologies that helps in green ammonia production and reducing carbon emissions at low temperature. | $968.2K | Seed | May 01, 2022 |  |
| Alimetry | Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function. | $16.3M | Series A | Mar 01, 2022 |  |
| Rekover Therapeutics | Rekover Therapeutics is a healthcare company that develops therapies for repair of tissue damage caused by multiple sclerosis. |  | Seed | Jan 01, 2022 |  |
| RosterLab | RosterLab goal is to automate every part of the rostering process for healthcare. | $336.8K | Pre-Seed | Dec 17, 2021 |  |
| Mekonos | Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip. Mekonos is a Silicon Valley Venture-backed technology company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in drug discovery and development. | $25M | Series A | Nov 09, 2021 |  |
| Ampersand Technologies | Ampersand Technologies develops new generation of DNA amplification technologies for diagnostic purposes. |  | Pre-Seed | Nov 04, 2021 |  |

10 of 21 investments shown.

## Co-investors
- [Booster](https://shizune.co/investors/profile/booster-aa31) — VC Fund, 6 deals together
- [IP Group](https://shizune.co/investors/profile/ip-group-plc) — VC Fund, 4 deals together
- [K1W1](https://shizune.co/investors/profile/k1w1) — VC Fund, 4 deals together
- [New Zealand Growth Capital Partners](https://shizune.co/investors/profile/new-zealand-growth-capital-partners) — VC Fund, 4 deals together
- [Quidnet Ventures](https://shizune.co/investors/profile/quidnet-ventures) — VC Fund, 4 deals together
- [University of Auckland Inventors Fund](https://shizune.co/investors/profile/university-of-auckland-inventors-fund) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Icehouse Ventures](https://shizune.co/investors/profile/icehouse-ventures) — VC Fund
- [Enterprise Angels](https://shizune.co/investors/profile/enterprise-angels) — VC Fund
- [K1W1](https://shizune.co/investors/profile/k1w1) — VC Fund

## Featured in investor lists
- [All Investors in New Zealand](https://shizune.co/investors/investors-new-zealand)
- [All VC Funds in New Zealand](https://shizune.co/investors/vc-funds-new-zealand)
- [Health Care Investors in Oceania](https://shizune.co/investors/health-care-investors-oceania)
- [Health Care Investors in New Zealand](https://shizune.co/investors/health-care-investors-new-zealand)
- [Health Care VC Funds in New Zealand](https://shizune.co/investors/health-care-vc-funds-new-zealand)
- [Biotech VC Funds in Oceania](https://shizune.co/investors/biotech-vc-funds-oceania)

## FAQ

### What does Matū Group invest in?

Matū Group invests primarily in Biotechnology, Health Care and Manufacturing startups, most often at Seed and Pre-Seed stage. Most of the 21 investments tracked by Shizune back companies in New Zealand. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Matū Group's check size?

Matū Group typically joins rounds of $473k–$2.2M at Seed, $337k–$972k at Pre-Seed and $2.3M–$25M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Matū Group participates in.

### When did Matū Group last invest?

The most recent investment recorded for Matū Group closed in Jun 2023. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co